Document is current

Article History

Received: 6 January 2026

Accepted: 13 May 2026

First Online: 29 May 2026

Declarations

: This study has been approved by the Ethics Committee of Shenzhen Hospital, Cancer Hospital of the Chinese Academy of Medical Sciences (registration number JS2025-12-1). Any protocol amendment will be approved by the IRB first, then communicated to investigators (by email), participants (updated consent if needed), trial registry (ChiCTR2500114052), journal (upon publication), and regulators (as required). All changes will be versioned and dated. This study protocol follows the feasibility study principle. All participants and their legal guardians will be informed of the purpose of the study. All participants or their legal guardians must sign a written informed consent form in accordance with the Declaration of Helsinki before enrollment. Participants and their relatives or legal guardians may withdraw consent at any time. All participant information and data will be stored securely and identified only by a coded ID number to ensure participant privacy. No specific ancillary care is planned beyond standard postoperative care. Post-trial, participants return to standard hospital protocols. Any harm directly related to trial participation will be compensated by the study sponsor in accordance with local regulations.

: The personal information of the study participants will not be released.

: The authors declare no competing interests.